Structural basis for inhibition of the AAA-ATPase Drg1 by diazaborine

Michael Prattes,Irina Grishkovskaya,Victor-Valentin Hodirnau,Ingrid Rössler,Isabella Klein,Christina Hetzmannseder,Gertrude Zisser,Christian C. Gruber,Karl Gruber,David Haselbach,Helmut Bergler
DOI: https://doi.org/10.1038/s41467-021-23854-x
IF: 16.6
2021-06-09
Nature Communications
Abstract:Abstract The hexameric AAA-ATPase Drg1 is a key factor in eukaryotic ribosome biogenesis and initiates cytoplasmic maturation of the large ribosomal subunit by releasing the shuttling maturation factor Rlp24. Drg1 monomers contain two AAA-domains (D1 and D2) that act in a concerted manner. Rlp24 release is inhibited by the drug diazaborine which blocks ATP hydrolysis in D2. The mode of inhibition was unknown. Here we show the first cryo-EM structure of Drg1 revealing the inhibitory mechanism. Diazaborine forms a covalent bond to the 2′-OH of the nucleotide in D2, explaining its specificity for this site. As a consequence, the D2 domain is locked in a rigid, inactive state, stalling the whole Drg1 hexamer. Resistance mechanisms identified include abolished drug binding and altered positioning of the nucleotide. Our results suggest nucleotide-modifying compounds as potential novel inhibitors for AAA-ATPases.
multidisciplinary sciences
What problem does this paper attempt to address?